CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,189 | 97,223 | ||
| 2025-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,189 | 0 | ||
| 2025-01-01 | LEONARD JOHN M President and CEO | Option exercise | +7,850 | 967,922 | ||
| 2025-01-01 | LEONARD JOHN M President and CEO | Option exercise · Restricted Stock Unit | −7,850 | 0 | ||
| 2025-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +3,500 | 86,354 | ||
| 2025-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Restricted Stock Unit | −3,500 | 0 | ||
| 2024-10-02 | Dube Michael P VP, Chief Accounting Officer | Sale | −2,012 | $19.01 | $38K | 47,012 |
| 2024-07-22 | Dulac Edward J III EVP, Chief Financial Officer | Grant or award | +66,324 | 66,324 | ||
| 2024-07-22 | Dulac Edward J III EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +96,219 | 96,219 | ||
| 2024-07-01 | Clark Eliana EVP, Chief Technical Officer | Sale | −405 | $22.93 | $9K | 71,470 |
| 2024-07-01 | Dube Michael P VP, PAO and Interim PFO | Grant or award | +17,801 | 49,024 | ||
| 2024-06-17 | Verwiel Frank Director | Sale 10b5-1 | −1,505 | $25.00 | $38K | 17,948 |
| 2024-06-13 | Goff Brian Director | Grant or award | +15,409 | 15,409 | ||
| 2024-06-13 | Goff Brian Director | Grant or award · Stock Option (right to buy) | +22,297 | 22,297 | ||
| 2024-06-12 | Verwiel Frank Director | Grant or award | +7,737 | 19,453 | ||
| 2024-06-12 | Verwiel Frank Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 | ||
| 2024-06-12 | Keresty Georgia Director | Grant or award | +7,737 | 23,883 | ||
| 2024-06-12 | Keresty Georgia Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 | ||
| 2024-06-12 | GOODMAN JESSE Director | Grant or award | +7,737 | 19,453 | ||
| 2024-06-12 | GOODMAN JESSE Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 |
Page 6 of 40 · 783 trades